Full Press Release Details
FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website athttps://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.
About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA®(vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA®TRIPLE PAK®(vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA®DUAL PAK®(vonoprazan tablets, amoxicillin capsules) for the treatment ofH. pyloriinfection in adults. For more information about Phathom, visit the company’s website atwww.phathompharma.comand follow onLinkedInandX.
MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com
INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com
© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.